NEW YORK, NY — March 22, 2002 — Forest Laboratories, Inc. announced that clinical study results were presented March 20th at the annual meeting of the Anxiety Disorders Association of America (ADAA), including a trial demonstrating that Lexapro (escitalopram oxalate) significantly reduced anxiety in patients with generalized anxiety disorder (GAD) when compared to placebo.
Other research presented at the meeting included a study demonstrating that, when compared to placebo, Lexapro significantly reduced panic symptoms in patients with panic disorder, including panic attack frequency and severity, and a study showing that Lexapro significantly improved symptoms in patients with social anxiety disorder (SAD) as compared to placebo. Lexapro, the single-active isomer of Celexa (citalopram HBr), is an investigational selective serotonin reuptake inhibitor (SSRI).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!